Abstract

This study was designed to evaluate the interaction between total adiponectin (ADPN)and metabolic syndrome (MetS) on cardiac changes in 135 subjects with and withoutMetS, subgrouped according to normal or low ADPN. Left ventricular internal diameter(LVID/h), LV mass (LVM), LVM index (LVMI), interventricular septal thickness (IVST),relative wall thickness (RWT) and LV ejection fraction (EF) by echocardiography anddiastolic parameters, by pulsed-wave Doppler were calculated. BMI, LVM, LVMI, LVID/h, IVST and RWT values were significantly (p<0.05) higher inboth groups with low ADPN. Prevalence of left ventricular hypertrophy (p<0.001) andcoronary artery disease (p<0.01) was significantly higher in both low ADPN groups.LVMI correlated directly with BMI (p<0.001), (p<0.001), MetS (p<0.001) and inverselywith ADPN (p<0.0001). ADPN and BMI resulted independently associated with LVMI.In conclusion, our data suggest that hypoadiponectinemia might be considered a novel“cardiometabolic biomarker”. Accordingly, circulating ADPN might become a newtarget in the management of cardiometabolic syndrome.
Lingua originaleEnglish
Numero di pagine5
RivistaDefault journal
Volume1
Stato di pubblicazionePublished - 2014

Fingerprint

Adiponectin
Biomarkers
Left Ventricular Hypertrophy
Echocardiography
Arteries

Cita questo

@article{9ff6f965851848c8a9e1e289fe4d5b20,
title = "May Adiponectin be considered as a NovelCardiometabolic Biomarker?",
abstract = "This study was designed to evaluate the interaction between total adiponectin (ADPN)and metabolic syndrome (MetS) on cardiac changes in 135 subjects with and withoutMetS, subgrouped according to normal or low ADPN. Left ventricular internal diameter(LVID/h), LV mass (LVM), LVM index (LVMI), interventricular septal thickness (IVST),relative wall thickness (RWT) and LV ejection fraction (EF) by echocardiography anddiastolic parameters, by pulsed-wave Doppler were calculated. BMI, LVM, LVMI, LVID/h, IVST and RWT values were significantly (p<0.05) higher inboth groups with low ADPN. Prevalence of left ventricular hypertrophy (p<0.001) andcoronary artery disease (p<0.01) was significantly higher in both low ADPN groups.LVMI correlated directly with BMI (p<0.001), (p<0.001), MetS (p<0.001) and inverselywith ADPN (p<0.0001). ADPN and BMI resulted independently associated with LVMI.In conclusion, our data suggest that hypoadiponectinemia might be considered a novel“cardiometabolic biomarker”. Accordingly, circulating ADPN might become a newtarget in the management of cardiometabolic syndrome.",
author = "Antonio Pinto and {Di Chiara}, Tiziana and Christiano Argano and Rosario Scaglione and Alessandra Scaglione and Salvatore Corrao",
year = "2014",
language = "English",
volume = "1",
journal = "Default journal",

}

TY - JOUR

T1 - May Adiponectin be considered as a NovelCardiometabolic Biomarker?

AU - Pinto, Antonio

AU - Di Chiara, Tiziana

AU - Argano, Christiano

AU - Scaglione, Rosario

AU - Scaglione, Alessandra

AU - Corrao, Salvatore

PY - 2014

Y1 - 2014

N2 - This study was designed to evaluate the interaction between total adiponectin (ADPN)and metabolic syndrome (MetS) on cardiac changes in 135 subjects with and withoutMetS, subgrouped according to normal or low ADPN. Left ventricular internal diameter(LVID/h), LV mass (LVM), LVM index (LVMI), interventricular septal thickness (IVST),relative wall thickness (RWT) and LV ejection fraction (EF) by echocardiography anddiastolic parameters, by pulsed-wave Doppler were calculated. BMI, LVM, LVMI, LVID/h, IVST and RWT values were significantly (p<0.05) higher inboth groups with low ADPN. Prevalence of left ventricular hypertrophy (p<0.001) andcoronary artery disease (p<0.01) was significantly higher in both low ADPN groups.LVMI correlated directly with BMI (p<0.001), (p<0.001), MetS (p<0.001) and inverselywith ADPN (p<0.0001). ADPN and BMI resulted independently associated with LVMI.In conclusion, our data suggest that hypoadiponectinemia might be considered a novel“cardiometabolic biomarker”. Accordingly, circulating ADPN might become a newtarget in the management of cardiometabolic syndrome.

AB - This study was designed to evaluate the interaction between total adiponectin (ADPN)and metabolic syndrome (MetS) on cardiac changes in 135 subjects with and withoutMetS, subgrouped according to normal or low ADPN. Left ventricular internal diameter(LVID/h), LV mass (LVM), LVM index (LVMI), interventricular septal thickness (IVST),relative wall thickness (RWT) and LV ejection fraction (EF) by echocardiography anddiastolic parameters, by pulsed-wave Doppler were calculated. BMI, LVM, LVMI, LVID/h, IVST and RWT values were significantly (p<0.05) higher inboth groups with low ADPN. Prevalence of left ventricular hypertrophy (p<0.001) andcoronary artery disease (p<0.01) was significantly higher in both low ADPN groups.LVMI correlated directly with BMI (p<0.001), (p<0.001), MetS (p<0.001) and inverselywith ADPN (p<0.0001). ADPN and BMI resulted independently associated with LVMI.In conclusion, our data suggest that hypoadiponectinemia might be considered a novel“cardiometabolic biomarker”. Accordingly, circulating ADPN might become a newtarget in the management of cardiometabolic syndrome.

UR - http://hdl.handle.net/10447/101994

M3 - Article

VL - 1

JO - Default journal

JF - Default journal

ER -